In recent years, conjugate drugs have become one of the very hot tracks in the pharmaceutical industry, in addition to the hot research and development of traditional ADCs, new conjugate drugs have also shown a hundred flowers
.
Some new types of drug conjugates are emerging, including PDC (peptide conjugate), RDC (nuclear conjugate), SMDC (small molecule conjugate), AOC (antibody oligonucleotide conjugate), ADeC (antibody degrading conjugate), etc
.
Among them, the structure of PDC is similar to that of antibody drug conjugates (ADCs), and is composed of
three parts: peptide, cytotoxic drug and linker.
Compared with ADC drugs, PDC drugs have the advantages of small molecular weight, strong tumor penetration, low immunogenicity and low production cost, and are gradually becoming a new generation of targeted anti-cancer drugs after small molecule drugs, monoclonal antibodies and ADC drugs
.
At the same time, the layout of domestic and foreign pharmaceutical companies in this field is also accelerating
.
For example, PDC leader PeptiDream recently announced collaborations and licensing agreements with Merck and Eli Lilly to discover and develop novel peptidedrugconjugates (PDCs) targeting multiple drug targets, totaling more than $3.
3 billion
.
Specifically, on December 22, 2022, Merck and PeptiDream entered into an agreement to discover and develop new PDCs based on PeptiDream's drug discovery and development platform technology PDPS (Peptide Discovery Platform System), and PeptiDream will receive an upfront payment and may receive a total of up to $2.
1 billion in development, approval, and sales milestone fees
in the future.
In addition, the Company is entitled to royalties
based on net sales after commercialization.
Merck will be responsible for all development of PDCs in this program
On December 26, Eli Lilly and PeptiDream signed an agreement that based on the PDPS platform, PeptiDream will be responsible for the discovery and optimization of peptides, while Lilly will be responsible for the discovery and optimization of payloads and the development of PDC products in this cooperation
.
PeptiDream will receive an upfront payment and may receive a total of up to $1.
235 billion in development, approval, and sales milestone fees
.
In addition, PeptiDream has the right to receive royalties
for commercial sales.
In addition to multinational pharmaceutical companies, in China, with the rapid development of domestic pharmaceutical companies, many companies have laid out in this field in recent years and ushered in new breakthroughs
.
Among them, CBP-1008, a dual-targeted-ligand conjugate developed by Tongyi Pharma based on the Bi-XDC technology platform, has progressed rapidly and has been undergoing phase Ia clinical trials
.
In addition, also based on the Bi-XDC technology platform, Tongyi Pharmaceutical has also developed CBP-1018
, a second dual-ligand conjugate drug targeting FRα and PSMA and MMAE as the drug.
In addition, SNG1005, a new drug for breast cancer brain metastasis developed by Sinochem and Angiochem, is also conducting phase III clinical trials
in China.
It is reported that this is a conjugate formed by the combination of paclitaxel molecules and chemically synthesized polypeptides, and it is also a PDC project
with the highest progress in China.
At present, with the deepening of domestic and foreign pharmaceutical companies in the field of PDC and the continuous advancement of research and development, the indications of global representative PDC drug research and development have been very rich, including esophageal tumors, brain tumors, metastatic non-small cell lung cancer, gastric tumors, ovarian tumors, multiple myeloma, pancreatic tumors, advanced solid tumors, etc
.
The industry generally believes that the future market prospect of the drug will be very broad
.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
